Genesis Pharma's Radix Isatidis OKed in China
China's Genesis Pharmaceuticals Enterprises that the State Food and Drug Administration granted approval for the firm to start producing and distributing Radix Isatidis Dispersible Tablets.
Radix Isatidis is a herbal-based traditional Chinese medicine used to cure viral influenza. It is very popular in China because people there believe it has fewer side affects than western medicines. Most Radix Isatidis products are in powder form,and have to be dissolved in hot water. Genesis will be the only company in China to manufacture its product in dispersible tablet form. Radix Isatidis Dispersible Tablets will be more convenient to take, easier to absorb and are more stable than products in powder form, the firm claims.
The company will start distributing its tablets within three months, and will make this medicine widely available to customers throughout China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze